Millennium | Clinicians | Oncology | VELCADE

	MULTIPLE MYELOMA



	MECHANISM
	LANDMARK PHASE 3 APEX TRIAL
	SURVIVAL
	TREATMENT TIMING
	RENAL IMPAIRMENT
	LENGTH OF THERAPY
	RETREATMENT
	SAFETY PROFILE
-	Peripheral Neuropathy
-	Transient Thrombocytopenia
	DOSE MODIFICATION GUIDELINES
	HANDLING AND ADMINISTRATION
	IMPORTANT SAFETY INFORMATION
	REIMBURSEMENT
	ADDITIONAL INFORMATION
	REFERENCES

THE POWER OF PROTEASOME INHIBITION^®

Unique Mechanism of Action Shown in Nonclinical Studies^{1, 12-14}

For more detailed explanations of the proteasome and proteasome inhibition, click here to access an animated video.

Please click here to view additional important safety information.

For full Prescribing Information click here. (pdf) (74KB)

For further information about VELCADE^® (bortezomib) for Injection, call 1-866-VELCADE (U.S. clinicians only).